Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Shares Sold by Sunbelt Securities Inc.

Sunbelt Securities Inc. trimmed its stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 13.5% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 160,225 shares of the biotechnology company’s stock after selling 25,050 shares during the quarter. Sunbelt Securities Inc. owned approximately 0.11% of Aurinia Pharmaceuticals worth $915,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Vermillion & White Wealth Management Group LLC acquired a new position in shares of Aurinia Pharmaceuticals in the fourth quarter worth $30,000. Banque Cantonale Vaudoise raised its holdings in shares of Aurinia Pharmaceuticals by 126.6% in the second quarter. Banque Cantonale Vaudoise now owns 9,684 shares of the biotechnology company’s stock worth $55,000 after acquiring an additional 5,410 shares during the last quarter. Virtu Financial LLC acquired a new position in shares of Aurinia Pharmaceuticals in the first quarter worth $78,000. Eagle Asset Management Inc. acquired a new position in shares of Aurinia Pharmaceuticals in the fourth quarter worth $92,000. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of Aurinia Pharmaceuticals by 67.4% in the first quarter. China Universal Asset Management Co. Ltd. now owns 27,802 shares of the biotechnology company’s stock worth $139,000 after acquiring an additional 11,189 shares during the last quarter. 36.83% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Aurinia Pharmaceuticals

In other Aurinia Pharmaceuticals news, insider Scott Michael Habig sold 18,249 shares of the business’s stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $5.31, for a total transaction of $96,902.19. Following the completion of the sale, the insider now owns 456,338 shares of the company’s stock, valued at $2,423,154.78. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 4.30% of the stock is owned by company insiders.

Aurinia Pharmaceuticals Price Performance

Shares of NASDAQ:AUPH opened at $7.33 on Tuesday. The company has a market cap of $1.05 billion, a P/E ratio of -17.05 and a beta of 1.44. The company has a quick ratio of 4.82, a current ratio of 5.33 and a debt-to-equity ratio of 0.18. Aurinia Pharmaceuticals Inc. has a 52 week low of $4.71 and a 52 week high of $10.05. The business has a fifty day simple moving average of $6.36 and a 200-day simple moving average of $5.67.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings results on Thursday, August 1st. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.01. Aurinia Pharmaceuticals had a negative return on equity of 11.84% and a negative net margin of 24.31%. The firm had revenue of $57.10 million during the quarter, compared to the consensus estimate of $54.25 million. During the same quarter in the previous year, the business earned ($0.08) earnings per share. The firm’s quarterly revenue was up 37.6% compared to the same quarter last year. Equities research analysts forecast that Aurinia Pharmaceuticals Inc. will post 0.13 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on AUPH. HC Wainwright reissued a “buy” rating and issued a $13.00 price target on shares of Aurinia Pharmaceuticals in a report on Friday, September 6th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $10.00 price objective on shares of Aurinia Pharmaceuticals in a research report on Monday, September 16th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, Aurinia Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $10.00.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.